In vivo tumor growth inhibition by Solanum tuberosum aspartic protease 3 (StAP3) treatment.
Cancer
Melanoma
Plasma membrane interaction
Potato
Saposin-like domain (PSI)
Journal
Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
received:
02
12
2020
revised:
26
02
2021
accepted:
05
03
2021
pubmed:
27
3
2021
medline:
26
8
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
Solanum tuberosum aspartic Proteases (StAPs) show selective plasma membrane permeabilization, inducing cytotoxicity of cancer cells versus normal cells in vitro. Herein, we aimed to evaluate both StAP3 systemic toxicity and antitumoral activity against human melanoma in vivo. The toxicity of a single high dose of StAP3 (10 µg/g body weight, intraperitoneally) was assessed in a Balb/c mice model. Subcutaneous A375 human melanoma xenografts in athymic nude (nu/nu) mice were induced. Once tumors developed (mean larger dimension = 3.8 ± 0.09 mm), mice were StAP3-treated (6 µg/g body weight, subcutaneously under the tumor at a single dose). For both models, controls were treated with physiologic saline solution. StAP3-treated mice showed a significant inhibition of tumor growth (p < 0.05) compared with controls. No signs of toxicity were detected in StAP3-treated mice in both models. These results suggest the potential of these plant proteases as anticancer agents.
Identifiants
pubmed: 33766772
pii: S0960-894X(21)00185-2
doi: 10.1016/j.bmcl.2021.127959
pii:
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Plant Proteins
0
Aspartic Acid Proteases
EC 3.4.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
127959Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.